You are here
P&T December 2019
Program reduced use of IV hydromorphone and morphine.
Strict policies are needed to protect patients.
New treatmetnt has rapid onset of action.
Identifying the best evidence for DOAC use in certain populations.
Case report points to risk of ciprofloxacin–ceftriaxone combination.
Men might have benefited from getting a more complete ED story.
A good bye from Pharmacy and Therapeutics.
Congress divided on drug pricing legislation.
Istradefylline (Nourianz) as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.